Cardio Explorer CVC Study: validation in a low-prevalence population.

Cardio Explorer CVC Study: validation in a low-prevalence population.

Published study validates Cardio Explorer for use in primary diagnostics. The most important facts in brief.

Our most recent study, published in BMJ Open on 26/09/2022, confirms Cardio Explorer's validation in a low-prevalence population (a population in which the disease is rare - in this case, only about 16% of the Maastricht population). The study was conducted at Maastricht University Medical Centre (MUMC) under the direction of Prof. Dr. Hans-Peter Brunner-La Rocca. A total of 696 patients were included in the study, who were examined for the presence of coronary artery disease (CAD) at the Cardiovascular Clinic in Maastricht (CVC).

The study shows that the AI (artificial intelligence)-based Cardio Explorer model is able to detect the presence of dangerous narrowing of the heart arteries with a high degree of accuracy. By combining patient data, the model achieves accuracy comparable to the best non-invasive methods (CT, MRI). However, this is much more cost-effective and already available in primary diagnostics.

The quality of a test procedure can be compared using the ROC curve. The higher the area under the curve (AUROC), the better the validity. The Cardio Explorer achieves an AUROC of 0.87 as a risk prediction model and is thus far superior to all currently available methods for use by general practitioners and in the check-up/screening area. This means that the presence of a dangerous narrowing in the heart arteries can be quickly and reliably ruled out or detected for a large part of the population without further clarification. This makes Cardio Explorer one of the first methods whose high accuracy has also been proven in a general practitioner population.

More information about Cardio Explorer

To the CVC study

(Image source: BMJPublishing Group Limited)